Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CC-220 in Hepatic Impairment vs Healthy Subjects
NCT03824678Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of iberdomide in systemic lupus erythematosus (SLE) and multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last quantifiable concentration up to 5 days, Area under the plasma concentration-time curve from time zero extrapolated to infinity up to 5 days and 5 more. Started Feb 2019; status: completed.
02
Drugs
iberdomide
03
Conditions
systemic lupus erythematosus (SLE)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03824678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824678.